Aladar Szalay Sells 6,403 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,403 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $3.25, for a total transaction of $20,809.75. Following the sale, the insider now directly owns 1,249,327 shares in the company, valued at $4,060,312.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total transaction of $109,101.30.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

Shares of NASDAQ GNLX traded up $0.17 during midday trading on Wednesday, reaching $3.28. 160,323 shares of the company traded hands, compared to its average volume of 125,230. The stock has a 50-day moving average price of $5.41 and a 200 day moving average price of $10.31. Genelux Co. has a 52 week low of $3.06 and a 52 week high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Equities analysts expect that Genelux Co. will post -0.81 EPS for the current year.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Woodward Diversified Capital LLC lifted its holdings in shares of Genelux by 0.3% in the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after buying an additional 3,687 shares during the period. LifeSteps Financial Inc. lifted its holdings in Genelux by 26.6% in the 1st quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company’s stock valued at $285,000 after acquiring an additional 9,301 shares during the last quarter. Clarity Capital Partners LLC bought a new position in shares of Genelux during the 4th quarter valued at about $364,000. Tower Research Capital LLC TRC grew its stake in shares of Genelux by 216.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after purchasing an additional 2,021 shares during the last quarter. Finally, Apollon Wealth Management LLC acquired a new position in shares of Genelux in the 4th quarter worth approximately $196,000. 37.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on GNLX. HC Wainwright cut their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Benchmark reaffirmed a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.